Insider Selling: Alamar Biosciences (NASDAQ:ALMR) Major Shareholder Sells 111,313 Shares of Company Stock

Alamar Biosciences, Inc. (NASDAQ:ALMR) major shareholder Corporate Gp Vi Ltd. Qiming sold 111,313 shares of the stock in a transaction dated Tuesday, November 3rd. The stock was sold at an average price of $29.89, for a total transaction of $3,327,145.57. Following the transaction, the insider owned 158,967 shares of the company’s stock, valued at $4,751,523.63. This represents a 41.18% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Major shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Corporate Gp Vi Ltd. Qiming also recently made the following trade(s):

• On Monday, November 2nd, Corporate Gp Vi Ltd. Qiming sold 43,930 shares of Alamar Biosciences stock. The stock was sold at an average price of $29.84, for a total value of $1,310,871.20.
• On Friday, October 30th, Corporate Gp Vi Ltd. Qiming sold 143,706 shares of Alamar Biosciences stock. The shares were sold at an average price of $30.38, for a total value of $4,365,788.28.
• On Wednesday, October 28th, Corporate Gp Vi Ltd. Qiming sold 100,837 shares of Alamar Biosciences stock. The shares were sold at an average price of $32.77, for a total value of $3,304,428.49.
• On Tuesday, October 27th, Corporate Gp Vi Ltd. Qiming sold 84,894 shares of Alamar Biosciences stock. The stock was sold at an average price of $31.39, for a total value of $2,664,822.66.
• On Monday, October 26th, Corporate Gp Vi Ltd. Qiming sold 132,524 shares of Alamar Biosciences stock. The stock was sold at an average price of $30.52, for a total value of $4,044,632.48.
• On Friday, October 23rd, Corporate Gp Vi Ltd. Qiming sold 147,934 shares of Alamar Biosciences stock. The stock was sold at an average price of $30.59, for a total value of $4,525,301.06.
• On Thursday, October 22nd, Corporate Gp Vi Ltd. Qiming sold 133,811 shares of Alamar Biosciences stock. The shares were sold at an average price of $29.33, for a total value of $3,924,676.63.
• On Wednesday, October 21st, Corporate Gp Vi Ltd. Qiming sold 208,815 shares of Alamar Biosciences stock. The shares were sold at an average price of $30.31, for a total value of $6,329,182.65.
• On Tuesday, October 20th, Corporate Gp Vi Ltd. Qiming sold 142,004 shares of Alamar Biosciences stock. The shares were sold at an average price of $27.89, for a total value of $3,960,491.56.
• On Monday, October 19th, Corporate Gp Vi Ltd. Qiming sold 75,508 shares of Alamar Biosciences stock. The shares were sold at an average price of $26.34, for a total value of $1,988,880.72.

Alamar Biosciences Trading Down 1.5%

Shares of Alamar Biosciences stock traded down $0.40 on Thursday, reaching $26.99. The stock had a trading volume of 1,238,729 shares, compared to its average volume of 437,669. Alamar Biosciences, Inc. has a 1 year low of $18.84 and a 1 year high of $39.61. The stock has a market capitalization of $1.87 billion and a P/E ratio of -13.77. The company has a current ratio of 11.85, a quick ratio of 10.23 and a debt-to-equity ratio of 0.03. The stock’s 50 day moving average price is $30.38.

Alamar Biosciences (NASDAQ:ALMR) last released its quarterly earnings data on Wednesday, November 4th. The company reported ($0.19) EPS for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.03. The firm had revenue of $33.55 million during the quarter. On average, equities analysts anticipate that Alamar Biosciences, Inc. will post -1.22 EPS for the current fiscal year.

Wall Street Analyst Weigh In

ALMR has been the subject of a number of recent analyst reports. TD Cowen boosted their price target on shares of Alamar Biosciences from $34.00 to $36.00 and gave the company a “buy” rating in a research report on Wednesday. Stifel Nicolaus increased their price objective on Alamar Biosciences from $28.00 to $32.00 and gave the stock a “buy” rating in a research report on Tuesday, August 11th. Weiss Ratings downgraded Alamar Biosciences from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, October 23rd. Finally, JPMorgan Chase & Co. lifted their price objective on Alamar Biosciences from $32.00 to $35.00 and gave the company an “overweight” rating in a research note on Tuesday, August 11th. Four analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $33.00.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. China Universal Asset Management Co. Ltd. bought a new stake in Alamar Biosciences during the third quarter valued at approximately $196,000. Squarepoint Ops LLC purchased a new position in Alamar Biosciences in the 2nd quarter worth approximately $283,000. Sumitomo Mitsui Trust Group Inc. grew its stake in Alamar Biosciences by 18.5% in the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 66,913 shares of the company’s stock worth $2,280,000 after buying an additional 10,461 shares in the last quarter. State Street Corp purchased a new position in Alamar Biosciences in the 2nd quarter worth approximately $3,930,000. Finally, Wellington Management Group LLP bought a new position in shares of Alamar Biosciences in the 2nd quarter worth $12,407,000.

Alamar Biosciences News Summary

Here are the key news stories impacting Alamar Biosciences this week:

• Positive Sentiment: Alamar reported third-quarter revenue of $33.55 million, up 68% year over year, and a loss of $0.19 per share—narrower than analysts’ expected $0.22 loss. The company also raised its 2026 revenue outlook to $121 million–$123 million, supporting its growth outlook. Alamar Q3 revenue and guidance
• Positive Sentiment: Alamar is partnering with GSK on a large-scale proteomics study. The collaboration could raise the profile of its NULISA platform, though the announcement did not disclose financial terms. Alamar and GSK proteomics study
• Positive Sentiment: Analysts raised price targets: TD Cowen lifted its target to $36 and BofA Securities raised its target to $35. TD Cowen maintained a Buy rating. TD Cowen rating information BofA price target update
• Neutral Sentiment: The company plans to participate in upcoming investor conferences, providing opportunities to discuss its business and outlook, but no new financial guidance was reported in the announcement. Investor conference announcement
• Negative Sentiment: Major shareholder Corporate Gp Vi Ltd. Qiming sold shares in a series of transactions, including 187,636 shares on October 30 and November 2. The sales may pressure sentiment, although the reason for them was not disclosed. Major shareholder sales

Alamar Biosciences Company Profile

Alamar Biosciences, Inc (NASDAQ: ALMR) is a life sciences company focused on advancing proteomics and enabling earlier detection, diagnosis and monitoring of disease. The company develops technologies designed to measure very low levels of proteins in biological samples, supporting research in areas such as oncology, neurology, immunology and other complex diseases.

Its primary technology is the NULISA platform, a highly sensitive, multiplexed immunoassay system that combines affinity-based protein detection with digital counting.